Ghrelin for cachexia

被引:75
作者
Akamizu, Takashi [1 ]
Kangawa, Kenji [2 ]
机构
[1] Kyoto Univ, Fac Med, Translat Res Ctr, Ghrelin Res Project,Dept Expt Therapeut,Sakyo Ku, Kyoto 6068507, Japan
[2] Natl Cerebral & Cardiovasc Ctr Res Inst, Osaka 5658565, Japan
关键词
Anorexia; Sarcopenia; Catabolism; Anabolism; Growth hormone; GHS; GROWTH-HORMONE SECRETAGOGUE; STIMULATES FOOD-INTAKE; CHRONIC KIDNEY-DISEASE; CHRONIC-RENAL-FAILURE; LEAN BODY-MASS; UBIQUITIN LIGASES; NEUROPEPTIDE-Y; THERMAL-INJURY; GH RELEASE; APPETITE;
D O I
10.1007/s13539-010-0011-5
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Ghrelin, a natural ligand for the growth hormone (GH)-secretagogue receptor, is primarily produced in the stomach. Administration of ghrelin stimulates food intake and GH secretion in both animals and humans. Ghrelin is the only circulating hormone known to stimulate appetite in humans. As GH is an anabolic hormone, protein stores are spared at the expense of fat during conditions of caloric restriction. Ghrelin also inhibits the production of anorectic proinflammatory cytokines. Thus, ghrelin exhibits anti-cachectic actions via both GH-dependent and -independent mechanisms. Several studies are evaluating the efficacy of ghrelin in the treatment of cachexia caused by a variety of diseases, including congestive heart failure, chronic obstructive pulmonary disease, cancer, and end-stage renal disease. These studies will hopefully lead to the development of novel clinical applications for ghrelin in the future. These studies have also facilitated a better understanding of the molecular basis of the anti-catabolic effects of ghrelin. This review summarizes the recent advances in this area of research.
引用
收藏
页码:169 / 176
页数:8
相关论文
共 92 条
[1]   Effects of Ghrelin Administration After Total Gastrectomy: A Prospective, Randomized, Placebo-Controlled Phase II Study [J].
Adachi, Shinichi ;
Takiguchi, Shuji ;
Okada, Kazuyuki ;
Yamamoto, Kazuyoshi ;
Yamasaki, Makoto ;
Miyata, Hiroshi ;
Nakajima, Kiyokazu ;
Fujiwara, Yoshiyuki ;
Hosoda, Hiroshi ;
Kangawa, Kenji ;
Mori, Masaki ;
Doki, Yuichiro .
GASTROENTEROLOGY, 2010, 138 (04) :1312-1320
[2]   Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects [J].
Akamizu, T ;
Takaya, K ;
Irako, T ;
Hosoda, H ;
Teramukai, S ;
Matsuyama, A ;
Tada, H ;
Miura, K ;
Shimizu, A ;
Fukushima, M ;
Yokode, M ;
Tanaka, K ;
Kangawa, K .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2004, 150 (04) :447-455
[3]   Repeated administration of ghrelin to patients with functional dyspepsia: its effects on food intake and appetite [J].
Akamizu, Takashi ;
Iwakura, Hiroshi ;
Ariyasu, Hiroyuki ;
Hosoda, Hiroshi ;
Murayama, Toshinori ;
Yokode, Masayuki ;
Teramukai, Satoshi ;
Seno, Hiroshi ;
Chiba, Tsutomu ;
Noma, Shunichi ;
Nakai, Yoshikatsu ;
Fukunaga, Mikhiko ;
Nakai, Yoshihide ;
Kangawa, Kenji .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (04) :491-498
[4]   EFFECTS OF GHRELIN TREATMENT ON PATIENTS UNDERGOING TOTAL HIP REPLACEMENT FOR OSTEOARTHRITIS: DIFFERENT OUTCOMES FROM STUDIES IN PATIENTS WITH CARDIAC AND PULMONARY CACHEXIA [J].
Akamizu, Takashi ;
Iwakura, Hiroshi ;
Ariyasu, Hiroyuki ;
Murayama, Toshinori ;
Sumi, Eriko ;
Teramukai, Satoshi ;
Goto, Koji ;
Ohnishi, Eijiro ;
Akiyama, Haruhiko ;
Kawanabe, Keiichi ;
Nankaku, Manabu ;
Ichihashi, Noriaki ;
Tsuboyama, Tadao ;
Tamai, Ken ;
Kataoka, Masako ;
Nakamura, Takashi ;
Kangawa, Kenji .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2008, 56 (12) :2363-2365
[5]   Cachexia in chronic heart failure: prognostic implications and novel therapeutic approaches. [J].
Akashi Y.J. ;
Springer J. ;
Anker S.D. .
Current Heart Failure Reports, 2005, 2 (4) :198-203
[6]   Efficacy of ghrelin as a therapeutic approach for age-related physiological changes [J].
Ariyasu, Hiroyuki ;
Iwakura, Hiroshi ;
Yamada, Go ;
Nakao, Kazuwa ;
Kangawa, Kenji ;
Akamizu, Takashi .
ENDOCRINOLOGY, 2008, 149 (07) :3722-3728
[7]   Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: Comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone [J].
Arvat, E ;
Maccario, M ;
Di Vito, L ;
Broglio, F ;
Benso, A ;
Gottero, C ;
Papotti, M ;
Muccioli, G ;
Dieguez, C ;
Casanueva, FF ;
Deghenghi, R ;
Camanni, F ;
Ghigo, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (03) :1169-1174
[8]   Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment [J].
Ashby, Damien R. ;
Ford, Heather E. ;
Wynne, Katie J. ;
Wren, Alison M. ;
Murphy, Kevin G. ;
Busbridge, Mark ;
Brown, Edwina A. ;
Taube, David H. ;
Ghatei, Mohammad A. ;
Tam, Frederick W. K. ;
Bloom, Stephen R. ;
Choi, Peter .
KIDNEY INTERNATIONAL, 2009, 76 (02) :199-206
[9]   Ghrelin and its therapeutic potential for cachectic patients [J].
Ashitani, Jun-ichi ;
Matsumoto, Nobuhiro ;
Nakazato, Masamitsu .
PEPTIDES, 2009, 30 (10) :1951-1956
[10]   Associations between plasma ghrelin levels and body composition in end-stage renal disease:: a longitudinal study [J].
Ayala, ER ;
Pecoits, R ;
Heimbürger, O ;
Lindholm, B ;
Nordfors, L ;
Stenvinkel, P .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2004, 19 (02) :421-426